logo-loader

Cancer Diagnostics group VolitionRX looks ahead to 2018

Published: 05:02 04 Jan 2018 EST

Cameron Reynolds CEO of Volition RX (NYSE:VNRX) talks to Proactive about the company's low cost, easy to use blood test (requiring just a single drop) - called Nu.Q test. Detail here too on new patents granted this year, strengthening Volition's intellectual portfolio as well as how their new cost-effective research laboratory in Belgium will increase their profitability as well as their ability to launch even more products worldwide. Cameron says Volition's scientific team has tripled in the last two years allowing an increase in trials capacity massively, which means the company is spot-on target for 2018.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 36 minutes ago